Shineking Biological

Shineking Biological is a leading Chinese synthetic biology company focused on the development and industrial-scale production of high-value nutritional ingredients. The company specializes in Human Milk Oligosaccharides (HMOs), including 2'-fucosyllactose (2'-FL), which are essential for developing infant gut health and immunity. Utilizing a proprietary platform for enzyme engineering and microbial strain optimization, Shineking has established a robust pipeline of bio-based products that serve the global food, health, and pharmaceutical industries. In 2023, the company became one of the first in China to receive official approval for the use of synthetic biology-derived 2'-FL in infant formula. Headquartered in Beijing with large-scale manufacturing facilities, Shineking is backed by prominent investors such as GL Ventures and IDG Capital.